ImmunoPET in Multiple Myeloma—What? So What? Now What?

Despite constant progress over the past three decades, multiple myeloma (MM) is still an incurable disease, and the identification of new biomarkers to better select patients and adapt therapy is more relevant than ever. Recently, the introduction of therapeutic monoclonal antibodies (mAbs) (includi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancers (Basel)
Main Authors: Bailly, Clément, Chalopin, Benjamin, Gouard, Sébastien, Carlier, Thomas, Remaud-Le Saëc, Patricia, Marionneau-Lambot, Séverine, Moreau, Philippe, Touzeau, Cyrille, Kraeber-Bodere, Françoise, Bodet-Milin, Caroline, Chérel, Michel
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2020
Teme:
Perspective
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7352991/
https://ncbi.nlm.nih.gov/pubmed/32512883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12061467
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki